Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2013

Elan Severs Ties with Alkermes

  • Elan, through its wholly owned subsidiary, Elan Science Three, agreed to sell all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company. The sale is expected to close on February 6, 2013.

    In May of 2011, Elan sold its Elan Drug Technologies (EDT) formulation and manufacturing business to Alkermes in a cash and shares deal valued at $960 million. Under terms of that agreement Elan shareholders received $500 million in cash and a 25% equity stake in the merged Alkermes entity. In September of that year, upon the completion of the merger of EDT with Alkermes, Elan received 31,900,000 ordinary shares in the newly created Alkermes—a total transaction value estimated to be approximately $1 billion at the time. In March 2012, Elan sold 24,150,000 ordinary shares of Alkermes in an underwritten public offering worth approximately $381 million.

    After the closing, Elan will no longer own any ordinary shares of Alkermes.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »